MPM. E. Perminova

M. E. Perminova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


M. E. Perminova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia

    by Maria A. Dunaykina, L. N. Shelikhova, S. L. Blagov, M. A. Klimentova, M. E. Perminova, E. Yu. Osipova, R. V. Nikolaev, M. V. Efimenko, G. G. Solopova, D. N. Balashov, et al.

    Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using a TCRαβ/CD19 depletion platform is associated with a low incidence of graft-versus-host disease, however, delayed immune reconstitution increases the risk of opportunistic viral reactivation. Aim: to analyze the kinetics of pathogen-specific immune reconstitution and its impact on clinical outcomes of allo-HSCT. Materials and methods. We performed a retrospective analysis on a cohort of 265 children from the prospective database of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All patients underwent their first allo-HSCT from a haploidentical donor with TCRαβ/CD19 depletion between September 2016 and March 2022. Pathogen-specific T-cell responses were assessed by IFN-γ ELISPOT assays (cutoff ≥10 SFC/3 × 10⁵ MNC) on days +30, +60, +90, +180, and at 1 year after allo-HSCT. Results. For cytomegalovirus (CMV), the proportion of ELISPOT-positive patients increased from 38.5 to 70% during the first year after allo-HSCT. For adenovirus, the proportion of ELISPOT-positive patients was 7% on day +30, 16% on day +90, and 38–49% from day +180 to 1 year. For Epstein–Barr virus, the proportion of ELISPOT-positive patients reached 22% at 1 year after allo-HSCT. On day +30, SFC counts for CMV showed the strongest correlation with CD3⁺CD8⁺ T cells; by 1 year, this association was no longer evident (R² = 0.005; p = 0.058). CMV ELISPOT positivity on day +30 correlated with CMV reactivation (57% vs 42%; p = 0.012), reflecting the effect of antigenic stimulation on T cell expansion. On day +60, ELISPOT positivity predicted a more favorable course of viremia, including a shorter duration of viremia (4 weeks vs 6 weeks; p = 0.023) and a lower peak viral load (9587 copies/mL vs 23 525 copies/mL; p = 0.029). The cumulative risk of transplant-related mortality was 3% (95% confidence interval 2–6); the trend toward lower transplant-related mortality in patients with ELISPOT positivity on day +30 did not reach statistical significance (1% vs 4%; p = 0.798). Conclusion. Therefore, reconstitution of pathogen-specific immunity after allo-HSCT is antigen-dependent. The presence of virus-specific T cells is associated with more effective control of viremia.

  • Open Access

    The results of therapy with venetoclax, daratumumab and plerixafor as part of the conditioning regimen in chemotherapy-refractory acute leukemia in children

    by Maria Klimentova, Лариса Шелихова, M. A. Ilushina, S. Blagov, M. E. Perminova, А. М. Попов, S. A. Kashpor, Maria Fadeeva, Yulia Olshanskaya, Svetlana Glushkova, et al.

    The main outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in chemotherapy-refractory acute leukemia remain suboptimal due to a high relapse rate. The incorporation of targeted anti-leukemia agents into the conditioning regimens is a potential approach to improve the efficacy of HSCT. We assessed the safety and potential efficacy of the addition of venetoclax, daratumumab, and plerixafor to the conditioning regimens in children with chemotherapy-refractory acute leukemias who received allogeneic TCRab/CD19-depleted HSCT. We used data from a pilot study, as well as the data of patients from a retrospective cohort who received similar therapy according to the individual indications. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All 43 patients (33 acute myeloid leukemias (AML), 8 T-cell acute lymphoblastic leukemias (T-ALL) and 2 acute leukemias of ambiguous lineage) had active disease status at the time of transplantation. The preparative regimen included myeloablative conditioning based on either total body irradiation or treosulfan or melphalan. A haploidentical related donor was used as a graft source in 38 cases, while a fully matched related or unrelated donor was used in 5 cases. The engraftment was observed in 93% of cases, no excessive toxicity was noted. MRD-negative complete remission was achieved in 37 patients (86%). The cumulative incidence of grade II–IV acute graft-versus-host disease (GvHD) was 10%, and the cumulative incidence of chronic GvHD was 5%. At 2 years, transplant-related mortality was 7%, relapse incidence was 52%, event-free survival was 41%, and overall survival was 51%. The overall survival rate for the AML group was 58% and 25% for the T-ALL group. Our data show that the addition of targeted agents to the conditioning regimens is safe, however, does not significantly improve the results of HSCT in the study cohort of patients.


  • Open Access

    A case report of lymphoepithelioma-like carcinoma in an adolescent

    by M. E. Perminova, G. S. Ovsyannikova, L. L. Kazakova, A. V. Pshonkin, I. V. Sidorov, V. P. Bondarenko, A. I. Karachunskiy, N. V. Zhukov

    Here we report a case of EBV-positive lymphoepithelioma-like carcinoma of the abdominal and retroperitoneal lymph nodes in a 17-year-old girl. This case is of special interest because of the rarity of the diagnosis (especially in adolescents), the unusual location of the tumor, the patient’s history of infections and autoimmune diseases (autoimmune hepatitis, Crohn’s disease) and the absence of standard treatment guidelines for this tumor. The patient and her legal representatives gave their consent to the use of the patient’s data, including photographs, for research purposes and in publications.